Switch theme
Sign up to access all valuation multiples
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
2012
56
Last FY Revenue n/a
LTM EBITDA -$161M
-$169M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Atea Pharmaceuticals has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$161M.
In the most recent fiscal year, Atea Pharmaceuticals achieved revenue of n/a and an EBITDA of -$193M.
Atea Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Atea Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$161M | XXX | -$193M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$180M | XXX | -$193M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$171M | XXX | -$168M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Atea Pharmaceuticals's stock price is $3.
Atea Pharmaceuticals has current market cap of $255M, and EV of -$169M.
See Atea Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$169M | $255M | XXX | XXX | XXX | XXX | $-2.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Atea Pharmaceuticals has market cap of $255M and EV of -$169M.
Atea Pharmaceuticals's trades at n/a EV/Revenue multiple, and 0.9x EV/EBITDA.
Equity research analysts estimate Atea Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atea Pharmaceuticals has a P/E ratio of -1.5x.
See valuation multiples for Atea Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $255M | XXX | $255M | XXX | XXX | XXX |
| EV (current) | -$169M | XXX | -$169M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | 2.2x | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtea Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.4M for the same period.
Atea Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atea Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Atea Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atea Pharmaceuticals acquired XXX companies to date.
Last acquisition by Atea Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Atea Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Atea Pharmaceuticals founded? | Atea Pharmaceuticals was founded in 2012. |
| Where is Atea Pharmaceuticals headquartered? | Atea Pharmaceuticals is headquartered in United States of America. |
| How many employees does Atea Pharmaceuticals have? | As of today, Atea Pharmaceuticals has 56 employees. |
| Who is the CEO of Atea Pharmaceuticals? | Atea Pharmaceuticals's CEO is Dr. Jean-Pierre Sommadossi,PhD. |
| Is Atea Pharmaceuticals publicy listed? | Yes, Atea Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Atea Pharmaceuticals? | Atea Pharmaceuticals trades under AVIR ticker. |
| When did Atea Pharmaceuticals go public? | Atea Pharmaceuticals went public in 2020. |
| Who are competitors of Atea Pharmaceuticals? | Similar companies to Atea Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Atea Pharmaceuticals? | Atea Pharmaceuticals's current market cap is $255M |
| Is Atea Pharmaceuticals profitable? | Yes, Atea Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Atea Pharmaceuticals? | Atea Pharmaceuticals's last 12 months EBITDA is -$161M. |
| What is the current EV/EBITDA multiple of Atea Pharmaceuticals? | Current EBITDA multiple of Atea Pharmaceuticals is 1.0x. |
| What is the current FCF of Atea Pharmaceuticals? | Atea Pharmaceuticals's last 12 months FCF is -$78.2M. |
| What is the current EV/FCF multiple of Atea Pharmaceuticals? | Current FCF multiple of Atea Pharmaceuticals is 2.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
